Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17001873 | 0.83 | LMNA (0.46) | LMNAALDH1A1TSHRPOLBGAA | |
| Hydrochloric Acid SCHEMBL20292109 | 0.82 | LMNA (0.45) | LMNAALDH1A1TSHRPOLBGAA | |
| Glutamic Acid SCHEMBL6471927 | 0.80 | ALDH1A1 (0.41) | LMNAALDH1A1POLBL3MBTL1SMN1; SMN2 | |
| SCHEMBL14266758 | 0.79 | LMNA (0.47) | LMNAALDH1A1POLBSMN1; SMN2NPC1 | |
| SCHEMBL14256491 | 0.75 | LMNA (0.44) | LMNAALDH1A1TSHRPOLBGAA | |
| SCHEMBL11362948 | 0.74 | LMNA (0.46) | LMNAALDH1A1TSHRPOLBGAA | |
| SCHEMBL8205127 | 0.74 | CHRNB2 (0.41) | LMNAALDH1A1TSHRPOLBGAA | |
| SCHEMBL1989282 | 0.73 | SLC18A3 (0.51) | ALDH1A1HRH3 | |
| SCHEMBL18751629 | 0.73 | SLC18A3 (0.51) | ALDH1A1HRH3 | |
| SCHEMBL15539562 | 0.72 | SLC6A4 (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | claimed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | claimed |
| EP-1438020-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EpiCept Corporation (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040076648-A1 | Topical compositions and methods for treating pain | EPICEPT CORPORATION | 2004-04-22 | — | — | US | claimed |
| US-20030082214-A1 | Topical compositions and methods for treating pain | DISCOVER GROWTH FUND, LLC (VI) | 2003-05-01 | — | — | US | claimed |
| WO-2003015699-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EPICEPT CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| US-10456444-B2 | Pirin polypeptide and immune modulation | 4D PHARMA RESEARCH LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| US-20170326202-A1 | PIRIN POLYPEPTIDE AND IMMUNE MODULATION | CJ BIOSCIENCE, INC. (KR) | 2017-11-16 | — | — | US | disclosed |
| US-9579299-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2017-02-28 | — | — | US | disclosed |
| WO-2016027259-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2016-02-25 | — | — | WO | disclosed |
| EP-0461986-A1 | Derivatives of hexahydroazepines, procedure for their preparation and pharmaceutical compositions containing same | SANOFI (FR) | 1991-12-18 | — | — | EP | disclosed |
| US-5011834-A | Treating or preventing neuronal loss in ischemia, hypoxia, brain and spinal cord trauma, Alzheimer*s | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1991-04-30 | — | — | US | disclosed |
| US-4994446-A | Drug system | RAMOT - UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1991-02-19 | — | — | US | disclosed |
| WO-1990012575-A1 | PCP RECEPTOR LIGANDS AND THE USE THEREOF | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | LMNA 4650/4885ALDH1A1 3257/4885TSHR 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.